Results 1 to 10 of about 8,051 (163)

Growth of meibomian gland tissue after intraductal meibomian gland probing in patients with obstructive meibomian gland dysfunction [PDF]

British Journal of Ophthalmology, 2017
PurposeTo investigate the impact of meibomian gland probing (MGP) on meibomian gland (MG) area from the upper lids of patients with obstructive meibomian gland dysfunction (o-MGD).MethodsRetrospective study comparing pre-MGP/post-MGP non-contact infrared meibography results in patients with o-MGD, viewing signs of MG growth within total measurement ...
Maskin, Steven L, Testa, Whitney R
openaire   +2 more sources

Effectiveness of Intraductal Meibomian Gland Probing for Obstructive Meibomian Gland Dysfunction

Cornea, 2016
To evaluate the short-term effectiveness of intraductal meibomian gland probing using modified Maskin cannulas in patients with obstructive meibomian gland dysfunction.The study prospectively included 58 eyes of 30 patients with a diagnosis of meibomian gland dysfunction who were refractory to medical treatment for at least 6 months.
Sarman, Züleyha Şık, Çüçen, Bülent, Yüksel, Nurşen, Cengiz, Abdulkadir, Çağlar, Yusuf   +4 more
openaire   +4 more sources

Meibomian gland probing in patients with meibomian gland dysfunction

Indian Journal of Clinical and Experimental Ophthalmology, 2019
Purpose: To evaluate the efficacy of Meibomian gland probing for obstructive Meibomian gland dysfunction (O-MGD) using intraductal Meibomian gland probe. Materials and Methods: 30 patients with Obstructive MGD based on 1. Presence of lid tenderness/ lid margin congestion/ telangiectasia /viscous meibomian gland secretion on slit lamp examination; 2 ...
D Nirupama, B Hymavathi, L Prathima, T Sanjay Reddy, G Satyanarayana Reddy   +4 more
openaire   +1 more source

Meibomian Gland Morphology Is a Sensitive Early Indicator of Meibomian Gland Dysfunction [PDF]

American Journal of Ophthalmology, 2019
To investigate the relationship between meibomian gland (MG) morphology and clinical dry eye tests in patients with meibomian gland dysfunction (MGD).Cross-sectional study.Total 538 MGD patients and 21 healthy controls.MG loss on meibography images of upper (UL) and lower lids (LL) was graded on a scale of 0 (lowest degree of MG loss) to 3.
Muhammed Yasin Adil, Jiaxin Xiao, Jonatan Olafsson, Xiangjun Chen, Neil S. Lagali, Sten Ræder, Øygunn A. Utheim, Darlene A. Dartt, Tor P. Utheim   +8 more
openaire   +4 more sources

Repeatability of Meibomian Gland Contrast, a Potential Indicator of Meibomian Gland Function [PDF]

Cornea, 2018
Purpose: Meibomian gland contrast may be a potential indicator of gland health, especially among isotretinoin users. We aimed to develop a repeatable and reliable method for measuring Meibomian gland contrast from meibography images.
Yeh, Thao N, Lin, Meng C
openaire   +4 more sources

Congenital aniridia: European COST action ANIRIDIA‐NET guidelines for diagnosis, management and care

Acta Ophthalmologica, EarlyView.
Abstract Congenital aniridia is a rare ocular disorder affecting the majority of eye structures and can be associated with systemic manifestations. The main visible phenotypic characteristic is the partial or complete absence of the iris; however, foveal hypoplasia is a more frequent and reliable clinical sign. Other ocular comorbidities are associated
Davide Romano, Vito Romano, Alejandra Daruich, Giulio Ferrari, Matthieu Robert, Francesco Semeraro, Neil Lagali, Dominique Bremond‐Gignac, the ANIRIDIA‐NET Clinical Guidelines Working Group, Miriam Barbany, Claus Cursiefen, Stefano Ferrari, Francisco Figueiredo, Christina Grupcheva, Jesper Hjortdal, Elke Kreps, Erlend Landsend, Laura Mauring, Hilde Pedersen, Nora Szentmáry, Bogumil Wowra, the Aniridia‐Europa and Geniris Working Group, Sophie Valleix, Juan Álvarez de Toledo, James Lauderdale, Tor Paaske Utheim, Paolo Rama   +26 more
wiley   +1 more source

Outcome parameters in studies investigating dry eye disease: A systematic literature review

Acta Ophthalmologica, EarlyView.
Abstract The development of effective therapeutics for dry eye disease (DED) is challenging due to its complex pathophysiology, heterogeneous patient presentation and the significant failure rate of previous clinical development programs. This underlines the importance of the selection of appropriate endpoints for clinical trials.
Viktoria Pai, Doreen Schmidl, Liudmyla Petric, Patrick Janku, Theresa Lindner, Ulrich Graf, Jacqueline Chua, Leopold Schmetterer, Gerhard Garhöfer   +8 more
wiley   +1 more source

What is the incidence and clinical significance of dry eye disease in patients treated with immune checkpoint inhibitors? A systematic review and meta‐analysis of ocular immune‐related adverse events

Acta Ophthalmologica, EarlyView.
Abstract Purpose Immune checkpoint inhibitors (ICIs) have transformed cancer therapy but may cause immune‐related adverse events (irAEs), including dry eye disease (DED). This study aimed to quantify the incidence of ICI‐associated DED and to evaluate factors contributing to variability across studies.
Kai‐Yang Chen, Hoi‐Chun Chan, Chi‐Ming Chan   +2 more
wiley   +1 more source

Repeatability of keratometry depending on tear film osmolarity

Acta Ophthalmologica, EarlyView.
Abstract Purpose To determine the repeatability of keratometry and astigmatism measurements of patients depending on the tear film osmolarity using three different devices. Methods In this study, 97 eyes of 97 patients with a mean age of 64.92 ± 12.07 years received three repeated measurements with the IOLMaster 700 (Carl Zeiss Meditec, Jena, Germany),
David Schneider, Klemens Paul Kaiser, Petra Davidova, Thomas Kohnen, Tyll Jandewerth   +4 more
wiley   +1 more source

Novel drugs approved by the EMA, the FDA and the MHRA in 2025: A year in review

British Journal of Pharmacology, EarlyView.
Abstract In the 2025 novel drug mini‐review, one can take a full measure of the ingenuity that underlies current drug design and development, despite the year's smaller harvest (46 novel drugs) compared to 2024 (53) and 2023 (70). 54% of the novel drugs are first‐in‐class (FIC).
Andreas Papapetropoulos, Stavros Topouzis, Steve P. H. Alexander, Miriam M. Cortese‐Krott, Zsuzsanna Helyes, Kirill Martemyanov, Claudio Mauro, Nithyanandan Nagercoil, Reynold A. Panettieri Jr, Hemal H. Patel, Rainer Schulz, Barbara Stefanska, Gary J. Stephens, Nathalie Vergnolle, Xin Wang, Stephen Ward, Péter Ferdinandy   +16 more
wiley   +1 more source